Syndicate content

Archive - Jun 1, 2019


Co-Expression Extrapolation (COXEN) Gene Analysis May Enable Prediction of Patient Response to Pre-Surgical Chemotherapy for Bladder Cancer

Data from a University of Colorado (CU) Cancer Center-led clinical trial show that a predictive tool called COXEN may show which bladder cancer patients will respond to pre-surgical chemotherapy, a step towards allowing doctors to offer such chemotherapy to patients likely to respond, while moving more efficiently to other treatment options with patients unlikely to benefit. Results of this trial will be presented Monday, June 3, at 8:00 am as an oral abstract at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting (ASCO abstract #4506) ( in Chicago, Illinois. The title of the abstract is “A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer.” "The idea is that for any individual tumor, its gene expression could tell us whether the cancer will respond to a certain kind of chemotherapy," says Thomas Flaig (photo), MD, Associate Dean for Clinical Research at CU School of Medicine, Chief Clinical Research Officer of UCHealth, and national principal investigator of the COXEN phase II clinical trial. "This is an important clinical application of a concept developed by investigators based in Colorado, which may have implications in predicting the response to chemotherapies across many cancer types." COXEN, which stands for “co-expression extrapolatiom,” was pioneered by former CU Cancer Center Director, Dan Theodorescu, MD, PhD, now Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai in Los Angeles. Dr. Thoedorescu's lab used 60 human-derived cancer cell lines curated by the National Cancer Institute to develop a gene expression approach to predicting the sensitivity of these cells to various chemotherapies.

Gypsy Moth Has Largest Moth/Butterfly Genome Ever Sequenced; Analysis May Reveal Secrets of Extraordinary Resistance of Gypsy Moth Cells to Arboviruses Infection & Aid in Efforts to Combat Arboviruses Like Zika That Infect Humans

The European gypsy moth (EGM) is perhaps the country's most famous invasive insect, a nonnative species accidentally introduced to North America in the 1860s when a few escaped from a breeding experiment in suburban Boston. The caterpillars have been slowly eating their way across the continent ever since, causing widespread defoliation. In research that could lead to better bioinsecticides to protect forests and orchards, Drs. Don Gammon and Nick Grishin of the University of Texas (UT) Southwestern have sequenced the genomes of the EGM and its even more destructive cousin, the Asian gypsy moth (AGM). Their work, published in the January 29, 2019 issue of PNAS, reveals that the gypsy moth has the largest moth or butterfly genome (number of DNA base pairs) ever sequenced. The PNAS article is titled “Gypsy Moth Genome Provides Insights into Flight Capability and Virus–Host Interactions.” "The European gypsy moth has spread as far west as Minnesota and as far south as North Carolina. The rather slow spread (about 13 miles a year) is partly due to the fact that EGM females are flightless and must walk or be blown by the wind to disperse," said Dr. Gammon, Assistant Professor of Microbiology and a W.W. Caruth, Jr. Scholar in Biomedical Research at UT Southwestern. "In contrast, females of the Asian gypsy moth subspecies, which inhabits Asia and eastern Russia, have larger, more developed wings, and can fly." If the Asian gypsy moth were to become established in the United States, it would pose an even greater economic threat due to its ability to spread more swiftly, Dr. Gammon added. To guard against that possibility, the US Department of Agriculture has surveillance programs at several ports and regularly sprays virus-based bioinsecticides in endangered forests to kill gypsy moth caterpillars.

Non-Invasive Test for Heart Blood Flow Developed; CO2/O2-Based Cardiac Functional MRI Provides “Totally Novel Way of Doing Cardiac Stress Testing to Identify Patients with Ischemic Heart Disease, Eliminates Existing Risks & Can Be Used on All Patients”

An international team led by scientists from Lawson Health Research Institute (Canada) and Cedars-Sinai Medical Center (USA) is the first to show that magnetic resonance imaging (MRI) can be used to measure how the heart uses oxygen for both healthy patients and those with heart disease. Reduced blood flow to the heart muscle is the leading cause of death in the Western world. Currently, the diagnostic tests available to measure blood flow to the heart require injection of radioactive chemicals or contrast agents that change the MRI signal and detect the presence of disease. There are small but finite associated risks and it is not recommended for a variety of patients including those with poor kidney function. More than 500,000 tests are performed each year in Canada. "This new method, cardiac functional MRI (cfMRI), does not require needles or chemicals being injected into the body," says Dr. Frank Prato, Lawson’s Assistant Director for Imaging. "It eliminates the existing risks and can be used on all patients." The results of the new study, titled "Accurate Needle-Free Assessment of Myocardial Oxygenation for Ischemic Heart Disease in Canines Using Magnetic Resonance Imaging" was published online on May 29, 2019 in Science Translational Medicine. The research team included researchers from Lawson; Cedars-Sinai Medical Center, and University of California (USA); King's College (UK); University Health Network (Canada) and the University of Toronto (Canada); Siemens Healthineers (Germany); and the University of Edinburgh (UK). "Our discovery shows that we can use MRI to study heart muscle activity," explains Dr. Prato. "We've been successful in using a pre-clinical model and now we are preparing to show this can be used to accurately detect heart disease in patients."

Exosomes from Transplanted Stem Cells Aid Recovery from Heart Attack in Animal Model; Analysis (Liquid Biopsy) of Circulating Exosomes from Transplanted Cells Can Allow Scientists/Physicians to Understand the Mechanism & Extent of Recovery

Stem-cell based therapies to strengthen the heart muscle and treat other diseases are beginning to show promise in human clinical trials. However, other than observing clinical outcomes, lack of a repeatable, time-sensitive, and noninvasive tool to assess the effectiveness of the transplanted cells within the target organ has slowed progress in the stem cell field. Researchers from the University of Maryland School of Medicine (UMSOM), the University of Pennsylvania, and Emory University theorized that a blood test could be used to track the efficacy of transplanted stem cells. They aimed to achieve their goal by analyzing tiny cellular components called exosomes, secreted from the transplanted stem cells into the recipient blood. The researchers tested their theory in rodent models of heart attack, or myocardial infarction, after transplanting two types of human cardiac stem cells and monitoring their circulating exosomes. The researchers found that circulating exosomes delivered cell components to the target heart muscle cells, resulting in cardiac repair. The results of their work were published online on May 22, 2019 in Science Translational Medicine. The article is titled “Circulating Exosomes Derived from Transplanted Progenitor Cells Aid the Functional Recovery of Ischemic Myocardium.”“Exosomes contain the signals of the cells they’re derived from – proteins, as well as nucleic acids and micro ribonucleic acids (miRNAs) – which affect receptor cells and remodel or regenerate the organ we’re targeting,” said study co-senior author Sunjay Kaushal, PhD, MD, Professor of Surgery at UMSOM and Director of Pediatric Cardiac Surgery at the University of Maryland Children’s Hospital.